Avinger reports second quarter 2023 results

Redwood city, ca / accesswire / july 27, 2023 / avinger, inc. (nasdaq:avgr), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the second quarter ended june 30, 2023. second quarter and recent highlights second quarter revenue of $2.0 million, and gross margin of 30% received 510(k) clearance and initiated limited launch for tigereye st, avinger's next generation image-guided cto-crossing device, with full commercial launch anticipated in the third quarter received 510(k) clearance for the new pantheris lv (large vessel) image-guided atherectomy device, and initiated limited launch in the third quarter advanced development of the first-ever image-guided coronary cto-crossing system through successful completion of the first round of animal studies and preparing for a second round of animal studies at a leading clinical center in the third quarter continued to generate excellent clinical outcomes data in the treatment of advanced disease in the pantheris sv image-btk study (small vessel, below-the-knee), with full enrollment expected to be completed in the third quarter avinger's technology, products and clinical data featured in multiple key opinion leader (kol) presentations at the charing cross, new cardiovascular horizons and linc clinical conferences, with additional podium presentations scheduled at the amp conference in august "we received 510(k) clearance for two exciting new devices in the second quarter, completing development of the most advanced peripheral products portfolio in the industry, and providing the opportunity for two important new product launches in the second half of this year," commented jeff soinski, avinger's president and ceo.
AVGR Ratings Summary
AVGR Quant Ranking